263 related articles for article (PubMed ID: 15289308)
21. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
22. Cell growth- and P53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells.
Yu L; Ugai S; O-Wang J; Namba M; Kadomatsu K; Muramatsu T; Matsubara S; Sakiyama S; Tagawa M
Oncol Rep; 2003; 10(5):1301-5. PubMed ID: 12883697
[TBL] [Abstract][Full Text] [Related]
23. Promoter of TRAIL-R2 gene.
Yoshida T; Sakai T
Vitam Horm; 2004; 67():35-49. PubMed ID: 15110170
[TBL] [Abstract][Full Text] [Related]
24. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
25. AP2alpha alters the transcriptional activity and stability of p53.
Stabach PR; Thiyagarajan MM; Woodfield GW; Weigel RJ
Oncogene; 2006 Apr; 25(15):2148-59. PubMed ID: 16288208
[TBL] [Abstract][Full Text] [Related]
26. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
[TBL] [Abstract][Full Text] [Related]
27. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
28. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).
Williamson EA; Wolf I; O'Kelly J; Bose S; Tanosaki S; Koeffler HP
Oncogene; 2006 Mar; 25(9):1391-9. PubMed ID: 16331276
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
31. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
32. The 5'-upstream region of human programmed cell death 5 gene contains a highly active TATA-less promoter that is up-regulated by etoposide.
Xu M; Cheng N; Gui L; Lai M; Wang Y; Xia D; Rui M; Zhang Y; Ma D
Gene; 2004 Mar; 329():39-49. PubMed ID: 15033527
[TBL] [Abstract][Full Text] [Related]
33. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.
Zhang D; Cao D; Russell R; Pizzorno G
Cancer Res; 2001 Sep; 61(18):6899-905. PubMed ID: 11559567
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
Goda AE; Yoshida T; Horinaka M; Yasuda T; Shiraishi T; Wakada M; Sakai T
Oncogene; 2008 May; 27(24):3435-45. PubMed ID: 18193086
[TBL] [Abstract][Full Text] [Related]
35. Identification of a p53-response element in the promoter of the proline oxidase gene.
Maxwell SA; Kochevar GJ
Biochem Biophys Res Commun; 2008 May; 369(2):308-13. PubMed ID: 18279664
[TBL] [Abstract][Full Text] [Related]
36. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
37. p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter.
Marcel V; Vijayakumar V; Fernández-Cuesta L; Hafsi H; Sagne C; Hautefeuille A; Olivier M; Hainaut P
Oncogene; 2010 May; 29(18):2691-700. PubMed ID: 20190805
[TBL] [Abstract][Full Text] [Related]
38. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
[TBL] [Abstract][Full Text] [Related]
39. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Liang SX; Richardson DR
Carcinogenesis; 2003 Oct; 24(10):1601-14. PubMed ID: 12869419
[TBL] [Abstract][Full Text] [Related]
40. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
